Everything PR News
PR Insights & Public Relations Strategy

FitBit Feeling the Pain

EPR Editorial TeamBy EPR Editorial Team2 min read
FitBit Feeling the Pain
Share
FitBit, the latest healthy living craze is under some serious fire. Bad timing, considering the bump the brand got from Christmas sales. On the heels of a celebrated smartwatch reveal, company stock was sent tumbling when a class action lawsuit was announced. According to various media reports, stock shares dropped 18 percent when the news of the lawsuit broke. The suit claims FitBit’s signature heart monitoring device – called PurePulse – reports inaccurate results, a potentially disastrous miscalculation considering the nature of the product’s purpose. How pervasive is the problem? The bad tech is present in FitBit’s Charge and Surge devices as well as the new Blaze smartwatch. While the tech FitBit uses is similar to that used by competitors at Apple and Garmin, to date, only FitBit faces rumors of wholesale failure. When your company’s basic ad message is “know your heart” news such as this presents a massive PR problem. Worse, the lawsuit lists specific issues about the technology’s failure. According to one plaintiff, when her FitBit clocked her heart rate at 82 beats per minute, her trainer counted 160 bpm. Sure, human error could be a factor … but double? Not good. And even worse, an article in Time magazine quoted a cardiologist who confirmed FitBit’s heart rate sensor “consistently reported” inaccurate results. To date, FitBit has responded with a strong denial. In a quote reported by Forbes, FitBit spokesmen said, “We do not believe this case has merit … FitBit is committed to making the best clip and wrist-based activity trackers on the market.” Nice to say, but, clearly, consumers are looking for more than a strong statement of purpose. At this point, FitBit’s best hope to make up the ground lost in the consumer market is to quickly and overwhelmingly challenge the messaging unleashed by the lawsuit. They need strong testimonials – from customers and medical experts – that not only dispute the claims in the suit but also put out specific counterclaims. Anything less and consumers will likely not bother listening. They’ll just pick a competitive product.
TagsPR Insights & Public Relations StrategyTechnology PR & Tech Communications
EPR Editorial Team
Written by
EPR Editorial Team
EPR Editorial Team - Author at Everything Public Relations

Other news

See all
ClickMind: The Swiss Platform Letting Brands Own Their Customer Data — In 24 Hours
EPR Editorial Team · 05/13/2026

ClickMind: The Swiss Platform Letting Brands Own Their Customer Data — In 24 Hours

ClickMind is a Swiss software company helping brands own their customer data. They offer white-label web and mobile platforms with 100% data sovereignty, deployable in 24 hours. The platform features CRM, direct messaging, document exchange, scheduling, and AI-powered chatbots.

ClickMind's AI Investor Relations Platform Is Replacing the PDF-and-Email Capital Raise
EPR Editorial Team · 05/13/2026

ClickMind's AI Investor Relations Platform Is Replacing the PDF-and-Email Capital Raise

Capital is moving on-app. The era of investor decks pushed via Dropbox, quarterly updates emailed as PDFs, and LP questions answered three days late by an associate is ending. Issuers are rebuilding investor relations the way DTC brands rebuilt retail — as a branded, mobile-first experience with an AI layer in the middle.

GrowMotion AG: Inside Europe's Swissmedic-Licensed Medical Cannabis Operator Going "Seed-to-Sell"
EPR Editorial Team · 05/13/2026

GrowMotion AG: Inside Europe's Swissmedic-Licensed Medical Cannabis Operator Going "Seed-to-Sell"

European medical cannabis is being built like pharma — not like dispensary retail. And Switzerland is the production hub. The cleanest case study is GrowMotion AG, a Zuchwil-based manufacturer that has spent five years engineering one of the most technologically advanced medical cannabis facilities on the continent.

Never Miss a Headline

Daily PR headlines, weekly long-form analysis, and our proprietary research drops — straight to your inbox.